👨‍💻 In case you missed it, the replay of the conference call for our third quarter 2025 Financial Results is available: https://t.co/O2Ut7gTsXz $IPH $IPHA #InnatePharma #BusinessUpdate #Immunotherapy #Biotech #Replay

Innate Pharma reports third quarter 2025 business update and financial results 📊🔬 More info in the press release: https://t.co/23c8BcNwsw $IPH $IPHA #InnatePharma #BusinessUpdate #Immunotherapy #biotech

📢 Innate Pharma is pleased to announce FDA clearance to proceed with TELLOMAK 3, a confirmatory Phase 3 trial of lacutamab in CTCL. More info: https://t.co/FVc4U6EuCM $IPH $IPHA #Lacutamab #ClinicalResearch #TCellLymphoma

We are pleased to host our conference call and webcast for Q3 2025 results and business update. 🔗 The live webcast will be available at the following link: https://t.co/O2Ut7gSV81 #InnatePharma #BusinessUpdate #Immunotherapy #Biotech

A great moment at our #lacutamab KOL event in New York! Thank you Dr. Pierluigi Porcu, ZS Associates & all participants for the insightful discussion on #CTCL & lacutamab, our lead asset. ▶️ Watch the replay: https://t.co/x5cKa87hHG #RareDisease #Oncology

📍D-1 before our Investor & Analyst Event in New York to discuss lacutamab, our lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase 3 initiation, with world experts and Innate Pharma management team. 🔗Register here:

Meet Dr. Pierluigi Porcu, world expert in T-cell lymphomas, discussing Phase 2 TELLOMAK trial at our lacutamab Investor & Analyst Event on October 28 🔗 Register here: https://t.co/yzsRvPmXg9 #IPHA #Lacutamab #TCellLymphoma #InvestorEvent

🎯 Live from #EORTC Innate Pharma presents encore data on lacutamab from the Phase 2 TELLOMAK trial in MF & SS, supporting its potential for #CTCL patients. Do not miss our upcoming event on Oct. 28! 🔗 Register here: https://t.co/yzsRvPmXg9 #Lymphoma #ClinicalTrials

What is Lacutamab? Lacutamab is a first in class antibody targeting KIR3DL2, developed in CTCL and PTCL. Join us at the lacutamab event to discuss clinical perspectives and market outlook! Register here: https://t.co/yzsRvPnv5H #RareDisease #CutaneousLymphoma #Event

📍 NYC Investor & Analyst Event Discuss lacutamab, our lead asset progressing towards potential accelerated approval in Sézary Syndrome and confirmatory phase 3 initiation. 🔗 Register here: https://t.co/yzsRvPmXg9 #CTCL #RareDisease #CutaneousLymphoma #BreakthroughTherapy

Join us on Oct. 28 at 8 am ET to discuss lacutamab clinical perspectives & market outlook. Hear from Dr. Porcu, an expert in T-cell lymphomas; ZS Associates, experts in life sciences and healthcare; and @InnatePharma management. 🔗 Register: https://t.co/x5cKa87Pxe #CTCL

#MeetInnate 📅 Nous avons le plaisir de vous rappeler que la prochaine rencontre actionnaires aura lieu le 25 septembre à 18H00 à Paris. Plus d'infos et inscription via ce lien https://t.co/2mMas6XSDv 🔗 #InnatePharma #Actionnaires #EvenementActionnaires #Bourse

Innate Pharma announces conference call and webcast for half-year results and Business Updates 👨‍💻 The live webcast will be available at the following link 🔗 https://t.co/eJW59tI7w9 #InnatePharma #Webinar #HalfYearResults

#MeetInnate Nous avons le plaisir de vous convier à une rencontre actionnaires ! 👥🤝 Plus d'infos et inscription via ce lien : https://t.co/ZBv88VNGEl #InnatePharma #Actionnaires #EvenementActionnaires #Bourse

🔬 Meet @EricVivier1 , Chief Scientific Officer of Innate Pharma, who will be speaking about the potential of innate immunity in cancer treatment in an educational session at the 19th International Congress of Immunology 2025, organized by the IUIS on August 21. $IPH $IPHA

🔬 Did you know? An Antibody-Drug Conjugate (ADC) is an innovative therapy primarily used in oncology. 👨‍⚕️ Why does it matter?  ADCs allow for the targeted delivery of powerful cytotoxic drug, significantly reducing toxicity compared to conventional chemotherapy. $IPH $IPHA

🔬 Meet Eric Vivier, Chief Scientific Officer of Innate Pharma, who will be speaker at FOCIS 2025 on June 25, during an educational session to highlight the potential of innate immunity in cancer treatment. $IPH $IPHA #InnatePharma #FOCiS2025 #Immunotherapy @FOCISimmunology

We’re pleased to share that the long-term follow-up data from the TELLOMAK trial, recently presented at ASCO, will be featured again as an encore presentation at the upcoming ICML in Lugano. $IPH $IPHA #InnatePharma #Lymphoma #ICML @icmlconf

#MeetInnate Come and meet members of our management team at the next IR conferences below 🚀 $IPH $IPHA #InnatePharma #IRmeeting #InvestorRelations

🚀 Innate Pharma at #EHA2025 Our CEO, Jonathan Dickinson, met with @bradloncar of @BioTechTV during the EHA 2025 congress to discuss our latest pipeline progress and our upcoming catalysts. 🧬 A great opportunity to share how Innate Pharma is advancing science to improve